Bifidobacterium lactis Fermented Milk Was Not Effective for Helicobacter pylori Eradication: A Prospective, Randomized, Double-Blind, Controlled Study
The management of Helicobacter pylori (H. pylori)
eradication is still a matter of discussion, full effectiveness is rarely
achieved, and it has many adverse effects. The use of probiotics may
be associated with better eradication rates and possibly prevention of
adverse events due to antibiotic therapy. The present clinical study
was undertaken to evaluate the efficacy of a specially designed
fermented milk product, containing Bifidobacterium lactis B420, on
the eradication of H. pylori infection in a prospective, randomized,
double-blind, controlled study in humans. Four test fermented milks
(FM) were specially designed in which counts of viable cells in all
products were 10^10 Log CFU. 100 mL-1 for Bifidobacterium lactis -
Bifidobacterium species 420. 190 subjects infected with H. pylori,
with previous diagnosis of functional dyspepsia according to Rome
III criteria entered the study. Bifidobacterium lactis B420,
administered twice a day for 90 days was not able to eradicate H.
pylori in Brazilian patients with functional dyspepsia.
[1] J. Tack, N. J. Talley, “Functional dyspepsia – symptoms, definitions and
validity of the Rome III criteria”, Nat Rev Gastroenterol Hepatol. vol.
10, pp. 134–41, 2013.
[2] S. L. Chen, “A review of drug therapy for functional dyspepsia”, J. of
Dig. Diseases, vol. 14, pp. 623–625, 2013.
[3] J. C. Yang, C. W. Lu and C. J. Lin, “Treatment of Helicobacter pylori
infection: Current status and future concepts”, World J Gastroenterol
vol. 14, n. 20(18), pp. 5283-5293, May 2014.
[4] C. Porras, J. Nodora, R. Sexton, C. Ferreccio, S. Jimenez, R. L.
Dominguez, P. Cook, G. Anderson, D. R. Morgan, L. H. Baker, E. R.
Greenberg and R. Herrero, “Epidemiology of Helicobacter pylori
infection in six Latin American countries” (SWOG Trial S0701). 2012.
[5] T. Navarro-Rodriguez, F. M. Silva, R. C. Barbuti, R. Mattar, J. P.
Moraes-Filho, M. N. Oliveira, C. S. Bogsan, D. Chinzon and J. N. Eisig,
“Association of a probiotic to a Helicobacter pylori eradication regimen
does not increase efficacy or decreases the adverse effects of the
treatment: a prospective, randomized, double-blind, placebo-controlled
study”. BMC Gastroenterology, vol. 13, pp. 56, 2013.
[6] L. G. Coelho, I. Maguinilk, S. Zaterka, J. M. Parente, M. do Carmo
Friche Passos and J. P. Moraes-Filho, “3rd Brazilian Consensus on
Helicobacter pylori”, Arq Gastroenterol. p. 50, Apr 2013.
[7] G. Felga, F. M. Silva, R. C. Barbuti, T. Navarro-Rodriguez, S. Zaterka
and J. N. Eisig, “Claritromycin-based triple therapy for Helicobacter
pylori in peptic ulcer patients”, J Infect Dev Countries, vol. 24, n. 11, pp.
712-6, Nov 2010.
[8] A. Sachdeva, S. Rawat and J. Nagpal, “Efficacy of fermented milk and
whey proteins in Helicobacter pylori eradication: A review”, World J
Gastroenterol, vol. 21, n. 3, pp. 724-737, January 2014.
[9] J. M. B. Vitor and F. F. Vale, “Alternative therapies for Helicobacter
pylori: probiotics and phytomedicine”, Fems Immunology and Medical
Microbiology, vol. 63, pp. 153-164, 2011.
[10] D. Lesbros-Pantoflickova, I. Corthesy-Theulaz and A. L. Blum,
“Helicobacter pylori and probiotics”, Journal of Nutrition vol. 137, pp.
812S-818S, 2007.
[11] S. Li, X. Huang, J. Z. Sui, S. Y. Chen, Y. T. Xie, Y. Deng, J. Wang, L.
Xie, T. J. Li, Y. He, Q. L. Peng, X. Qin and Z. Y. Zeng, “Meta-analysis
of randomized controlled trials on the efficacy of probiotics in
Helicobacter pylori eradication therapy in children”, Eur J Pediatr. vol.
173, pp. 153–161, 2014.
[12] C. P. M. Felley, “Probiotics and Helicobacter pylori”, Best Pract Res
Clin Gastroenterol. vol. 17, pp. 785-791, 2003.
[13] J. A. da Silva Medeiros, T. M. F. O. Goncalves, L. Boyanova, M. I. de
Correia Pereira, J. N. da Silva Paiva de Carvalho, A. M. de Sousa
Pereira and A. M. Silverio Cabrita, “Evaluation of Helicobacter pylori
eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone” European Journal of Clinical Microbiology &
Infectious Diseases vol. 30, pp. 555-559, 2011.
[14] M. Gotteland, O. Brunser and S. Cruchet, “Systematic review: are
probiotics useful in controlling gastric colonization by Helicobacter
pylori”, Alimentary Pharmacology & Therapeutics vol. 23, pp. 1077-
1086, 2006.
[15] Y. J. Yang and B. S. Sheu, “Probiotics-Containing Yogurts Suppress
Helicobacter pylori Load and Modify Immune Response and Intestinal
Microbiota in the Helicobacter pylori-Infected Children” Helicobacter
vol. 17, pp. 297-304, 2012.
[16] P. Michetti, “Lactobacilli for the management of Helicobacter pylori
nutrition” The International Journal of Applied and Basic Nutritional
Sciences vol. 17, pp. 268-269. 2001.
[17] C. Sunanliganon, D. Thong-Ngam, S. Tumwasorn and N. Klaikeaw,
“Lactobacillus plantarum B7 inhibits Helicobacter pylori growth and
attenuates gastric inflammation”, World Journal of Gastroenterology
vol. 18, pp. 2472-2480, 2012.
[18] B. S. Sheu, J. J. Wu, C. Y. Lo, H. W. Wu, J. H. Chen, Y. S. Lin, and M.
D. Lin, “Impact of supplement with Lactobacillus- and Bifidobacteriumcontaining
yogurt on triple therapy for Helicobacter pylori eradication”,
Alimentary Pharmacology & Therapeutics vol.16, pp. 1669-1675. 2002.
[19] Z. H. Wang, Q. Y. Gao and J. Y. Fang, “Meta-Analysis of the Efficacy
and Safety of Lactobacillus-containing and Bifidobacterium-containing
Probiotic Compound Preparation in Helicobacter pylori Eradication
Therapy”, Journal of Clinical Gastroenterology vol. 47, pp. 25-32.
2013.
[20] M. Wang, S. Ahrnes, B. Jeppsson and G. Molin, “Comparison of
bacterial diversity along the human intestinal tract by direct cloning and
sequencing of 16S rRNA genes”, FEMS Microbiology Ecology vol. 54,
pp. 219-231. 2005.
[21] J. Korzenik, C. Kitts, A. Pittler, A. Englebrektson, M. Sanders and T.
Klaenhammer, “A randomized, double-blind, controlled trial of
probiotics to minimize the disruption of gut flora as assessed by 16s
RNA terminal restriction fragment length polymorphism and culture
enumeration in healthy subjects undergoing antibiotic therapy”,
Gastroenterology vol. 128, pp. A662-A662. 2005.
[22] B. Foligne, S. Nutten, C. Grangette, V. Dennin, D. Goudercourt, S.
Poiret, J. Dewulf, D. Brassart, A. Mercenier and B. Pot, “Correlation
between in vitro and in vivo immunomodulatory properties of lactic acid
bacteria”, World Journal of Gastroenterology vol. 13, pp. 236-243.
2007.
[23] J. Tack and N. Talley, “Gastroduodenal disorders”, Am J Gastroenterol
vol. 105, pp. 757-763. 2010.
[24] P. Malfertheiner, F. Megraud, C. A. O'Morain, J. Atherton, A. T. Axon,
F. Bazzoli, G. F. Gensini, J. P. Gisbert, D. Y. Graham, T. Rokkas, E. M.
El-Omar and E. J. Kuipers, “Management of Helicobacter pylori
infection – the Maastrich IV/ Florence Consensus Report, European
Helicobacter Study Group”. Gut, vol. 61, n. 5, pp. 646-64. May 2012.
[25] M. Aguilera, M. Cerdà-Cuéllar and V. Martínez, “Antibiotic-induced
dysbiosis alters host-bacterial interactions and leads to colonic sensory
and motor changes in mice”, Gut Microbes. vol. 22, pp. 1-14. Dec 2014
[26] R. Zhu, K. Chen, Y. Y. Zheng, H.W. Zhang, J. S. Wang, Y. J. Xia, W.
Q. Dai, F. Wang, M. Shen, P. Cheng, Y. Zhang, C. F. Wang, J. Yang, J.
J. Li, J. Lu, Y. Q. Zhou and C. Y. Guo, “Meta-analysis of the efficacy of
probiotics in Helicobacter pylori eradication therapy”, World J
Gastroenterol. vol.21, n. 20, pp. 18013-21, Dec 2014.
[1] J. Tack, N. J. Talley, “Functional dyspepsia – symptoms, definitions and
validity of the Rome III criteria”, Nat Rev Gastroenterol Hepatol. vol.
10, pp. 134–41, 2013.
[2] S. L. Chen, “A review of drug therapy for functional dyspepsia”, J. of
Dig. Diseases, vol. 14, pp. 623–625, 2013.
[3] J. C. Yang, C. W. Lu and C. J. Lin, “Treatment of Helicobacter pylori
infection: Current status and future concepts”, World J Gastroenterol
vol. 14, n. 20(18), pp. 5283-5293, May 2014.
[4] C. Porras, J. Nodora, R. Sexton, C. Ferreccio, S. Jimenez, R. L.
Dominguez, P. Cook, G. Anderson, D. R. Morgan, L. H. Baker, E. R.
Greenberg and R. Herrero, “Epidemiology of Helicobacter pylori
infection in six Latin American countries” (SWOG Trial S0701). 2012.
[5] T. Navarro-Rodriguez, F. M. Silva, R. C. Barbuti, R. Mattar, J. P.
Moraes-Filho, M. N. Oliveira, C. S. Bogsan, D. Chinzon and J. N. Eisig,
“Association of a probiotic to a Helicobacter pylori eradication regimen
does not increase efficacy or decreases the adverse effects of the
treatment: a prospective, randomized, double-blind, placebo-controlled
study”. BMC Gastroenterology, vol. 13, pp. 56, 2013.
[6] L. G. Coelho, I. Maguinilk, S. Zaterka, J. M. Parente, M. do Carmo
Friche Passos and J. P. Moraes-Filho, “3rd Brazilian Consensus on
Helicobacter pylori”, Arq Gastroenterol. p. 50, Apr 2013.
[7] G. Felga, F. M. Silva, R. C. Barbuti, T. Navarro-Rodriguez, S. Zaterka
and J. N. Eisig, “Claritromycin-based triple therapy for Helicobacter
pylori in peptic ulcer patients”, J Infect Dev Countries, vol. 24, n. 11, pp.
712-6, Nov 2010.
[8] A. Sachdeva, S. Rawat and J. Nagpal, “Efficacy of fermented milk and
whey proteins in Helicobacter pylori eradication: A review”, World J
Gastroenterol, vol. 21, n. 3, pp. 724-737, January 2014.
[9] J. M. B. Vitor and F. F. Vale, “Alternative therapies for Helicobacter
pylori: probiotics and phytomedicine”, Fems Immunology and Medical
Microbiology, vol. 63, pp. 153-164, 2011.
[10] D. Lesbros-Pantoflickova, I. Corthesy-Theulaz and A. L. Blum,
“Helicobacter pylori and probiotics”, Journal of Nutrition vol. 137, pp.
812S-818S, 2007.
[11] S. Li, X. Huang, J. Z. Sui, S. Y. Chen, Y. T. Xie, Y. Deng, J. Wang, L.
Xie, T. J. Li, Y. He, Q. L. Peng, X. Qin and Z. Y. Zeng, “Meta-analysis
of randomized controlled trials on the efficacy of probiotics in
Helicobacter pylori eradication therapy in children”, Eur J Pediatr. vol.
173, pp. 153–161, 2014.
[12] C. P. M. Felley, “Probiotics and Helicobacter pylori”, Best Pract Res
Clin Gastroenterol. vol. 17, pp. 785-791, 2003.
[13] J. A. da Silva Medeiros, T. M. F. O. Goncalves, L. Boyanova, M. I. de
Correia Pereira, J. N. da Silva Paiva de Carvalho, A. M. de Sousa
Pereira and A. M. Silverio Cabrita, “Evaluation of Helicobacter pylori
eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone” European Journal of Clinical Microbiology &
Infectious Diseases vol. 30, pp. 555-559, 2011.
[14] M. Gotteland, O. Brunser and S. Cruchet, “Systematic review: are
probiotics useful in controlling gastric colonization by Helicobacter
pylori”, Alimentary Pharmacology & Therapeutics vol. 23, pp. 1077-
1086, 2006.
[15] Y. J. Yang and B. S. Sheu, “Probiotics-Containing Yogurts Suppress
Helicobacter pylori Load and Modify Immune Response and Intestinal
Microbiota in the Helicobacter pylori-Infected Children” Helicobacter
vol. 17, pp. 297-304, 2012.
[16] P. Michetti, “Lactobacilli for the management of Helicobacter pylori
nutrition” The International Journal of Applied and Basic Nutritional
Sciences vol. 17, pp. 268-269. 2001.
[17] C. Sunanliganon, D. Thong-Ngam, S. Tumwasorn and N. Klaikeaw,
“Lactobacillus plantarum B7 inhibits Helicobacter pylori growth and
attenuates gastric inflammation”, World Journal of Gastroenterology
vol. 18, pp. 2472-2480, 2012.
[18] B. S. Sheu, J. J. Wu, C. Y. Lo, H. W. Wu, J. H. Chen, Y. S. Lin, and M.
D. Lin, “Impact of supplement with Lactobacillus- and Bifidobacteriumcontaining
yogurt on triple therapy for Helicobacter pylori eradication”,
Alimentary Pharmacology & Therapeutics vol.16, pp. 1669-1675. 2002.
[19] Z. H. Wang, Q. Y. Gao and J. Y. Fang, “Meta-Analysis of the Efficacy
and Safety of Lactobacillus-containing and Bifidobacterium-containing
Probiotic Compound Preparation in Helicobacter pylori Eradication
Therapy”, Journal of Clinical Gastroenterology vol. 47, pp. 25-32.
2013.
[20] M. Wang, S. Ahrnes, B. Jeppsson and G. Molin, “Comparison of
bacterial diversity along the human intestinal tract by direct cloning and
sequencing of 16S rRNA genes”, FEMS Microbiology Ecology vol. 54,
pp. 219-231. 2005.
[21] J. Korzenik, C. Kitts, A. Pittler, A. Englebrektson, M. Sanders and T.
Klaenhammer, “A randomized, double-blind, controlled trial of
probiotics to minimize the disruption of gut flora as assessed by 16s
RNA terminal restriction fragment length polymorphism and culture
enumeration in healthy subjects undergoing antibiotic therapy”,
Gastroenterology vol. 128, pp. A662-A662. 2005.
[22] B. Foligne, S. Nutten, C. Grangette, V. Dennin, D. Goudercourt, S.
Poiret, J. Dewulf, D. Brassart, A. Mercenier and B. Pot, “Correlation
between in vitro and in vivo immunomodulatory properties of lactic acid
bacteria”, World Journal of Gastroenterology vol. 13, pp. 236-243.
2007.
[23] J. Tack and N. Talley, “Gastroduodenal disorders”, Am J Gastroenterol
vol. 105, pp. 757-763. 2010.
[24] P. Malfertheiner, F. Megraud, C. A. O'Morain, J. Atherton, A. T. Axon,
F. Bazzoli, G. F. Gensini, J. P. Gisbert, D. Y. Graham, T. Rokkas, E. M.
El-Omar and E. J. Kuipers, “Management of Helicobacter pylori
infection – the Maastrich IV/ Florence Consensus Report, European
Helicobacter Study Group”. Gut, vol. 61, n. 5, pp. 646-64. May 2012.
[25] M. Aguilera, M. Cerdà-Cuéllar and V. Martínez, “Antibiotic-induced
dysbiosis alters host-bacterial interactions and leads to colonic sensory
and motor changes in mice”, Gut Microbes. vol. 22, pp. 1-14. Dec 2014
[26] R. Zhu, K. Chen, Y. Y. Zheng, H.W. Zhang, J. S. Wang, Y. J. Xia, W.
Q. Dai, F. Wang, M. Shen, P. Cheng, Y. Zhang, C. F. Wang, J. Yang, J.
J. Li, J. Lu, Y. Q. Zhou and C. Y. Guo, “Meta-analysis of the efficacy of
probiotics in Helicobacter pylori eradication therapy”, World J
Gastroenterol. vol.21, n. 20, pp. 18013-21, Dec 2014.
@article{"International Journal of Biological, Life and Agricultural Sciences:69260", author = "R. C. Barbuti and M. N. Oliveira and N. P. Perina and C. Haro and P. Bosch and C. S. Bogsan and J. N. Eisig and T. Navarro-Rodriguez", title = "Bifidobacterium lactis Fermented Milk Was Not Effective for Helicobacter pylori Eradication: A Prospective, Randomized, Double-Blind, Controlled Study", abstract = "The management of Helicobacter pylori (H. pylori)
eradication is still a matter of discussion, full effectiveness is rarely
achieved, and it has many adverse effects. The use of probiotics may
be associated with better eradication rates and possibly prevention of
adverse events due to antibiotic therapy. The present clinical study
was undertaken to evaluate the efficacy of a specially designed
fermented milk product, containing Bifidobacterium lactis B420, on
the eradication of H. pylori infection in a prospective, randomized,
double-blind, controlled study in humans. Four test fermented milks
(FM) were specially designed in which counts of viable cells in all
products were 10^10 Log CFU. 100 mL-1 for Bifidobacterium lactis -
Bifidobacterium species 420. 190 subjects infected with H. pylori,
with previous diagnosis of functional dyspepsia according to Rome
III criteria entered the study. Bifidobacterium lactis B420,
administered twice a day for 90 days was not able to eradicate H.
pylori in Brazilian patients with functional dyspepsia.
", keywords = "Antibacterial Therapy, Bifidobacteria Fermented
milk, Helicobacter pylori, probiotics.", volume = "9", number = "3", pages = "270-4", }
